How Increase Tongue Retaining Device Sales Profitability?
Tongue Retaining Device Sales
Tongue Retaining Device Sales Strategies to Increase Profitability
Tongue Retaining Device Sales starts with exceptional financial health, achieving a 522% EBITDA margin in Year 1 on $70 million in revenue, and scaling to 624% by Year 5 This high profitability is driven by strong gross margins, but you must actively manage scaling costs like R&D and sales commissions This guide outlines seven strategies to push EBITDA margins past 60% and ensure that your high-dollar contribution products, like the premium device (priced at $495), dominate the sales mix You broke even in month one, but sustaining this requires optimizing Cost of Goods Sold (COGS) and controlling the 135% variable Selling, General, and Administrative (SG&A) costs
7 Strategies to Increase Profitability of Tongue Retaining Device Sales
#
Strategy
Profit Lever
Description
Expected Impact
1
Prioritize High-Contribution Devices
Revenue
Market the $495 Premium device more heavily than the $249 Basic device to lift overall profit per sale.
Generates nearly double the dollar profit per unit sold compared to the Basic model.
2
Maximize Accessory Attachment Rate
Revenue
Push sales of the $45 Cleaning Kit and $25 Liners immediately after the primary device purchase.
Creates predictable, high-frequency revenue streams, especially from Liners with 760% gross margins.
3
Reduce Material Input Costs
COGS
Negotiate better pricing for key components like the $2200 Titanium Screws and $1200 Polymer.
Aims to shave 5-10% off the $116 million in annual direct Cost of Goods Sold (COGS).
4
Scale Fixed Production Overhead
COGS
Ensure fixed overhead costs, like Factory Insurance (0.5%) and Regulatory Audit Fees (0.4%), grow slower than unit volume.
Boosts gross margin percentage by managing the 149% indirect COGS percentage more efficiently.
5
Optimize Variable SG&A Spend
OPEX
Review the 80% Digital Marketing budget and 30% Sales Commissions; shift volume toward direct clinical channels.
Reduces the overall 135% variable Selling, General, and Administrative (SG&A) burden without stalling growth.
6
Control Non-Scaling Fixed Costs
OPEX
Scrutinize the $28,200 monthly fixed operating expenses, especially the $5,000 Legal and Patent Maintenance.
Ensures fixed spending is defintely tied to strategic growth initiatives rather than legacy overhead.
7
Implement Strategic Price Increases
Pricing
Analyze if the medical device positioning supports immediate, targeted 3-5% price hikes now, rather than waiting for 2029.
Allows for immediate expansion of the current 52% EBITDA margin.
Tongue Retaining Device Sales Financial Model
5-Year Financial Projections
100% Editable
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Accounting Or Financial Knowledge
What is the true gross margin percentage for each device category?
The Premium device generates the highest absolute dollar contribution per sale, which is what truly drives bottom-line growth for Tongue Retaining Device Sales, even if the Travel model shows a slightly better percentage margin; honestly, you need to look past the percentage math when assessing What Are Operating Costs For Tongue Retaining Device Sales?. We need to confirm the direct Cost of Goods Sold (COGS) for each tier to see the real picture, not just the theoretical gross margin percentage.
Dollar Contribution Wins
Premium device yields $5,300 gross profit per unit.
Basic device contributes $2,450 in gross profit dollars.
Travel device profit is $3,280 per unit sold.
Focus on the absolute dollar impact, not just the percentage spread.
COGS vs. Price Reality
Premium COGS is $2,500 against a $7,800 price tag.
Basic device COGS is $1,200 on a $3,650 sale price.
Travel device COGS sits at $1,500, giving it a 68.6% margin.
If manufacturing lead times stretch past 14 days, supply chain costs defintely rise.
How can we shift the sales mix to maximize dollar contribution per transaction?
To maximize dollar contribution per transaction for your Tongue Retaining Device Sales operation, you need to aggressively shift volume toward the Premium model, as detailed in this guide on How To Launch Tongue Retaining Device Sales Business?. The Premium device yields a direct profit of $417, which dwarfs the $21250 profit from the Basic device, making volume allocation straightforward.
Dollar Contribution Priority
Premium sale price is $495; Basic is $249.
Premium yields $417 direct profit per unit.
Basic yields $21250 direct profit per unit.
Growth defintely requires focusing on unit volume of the Premium tier.
Why Absolute Dollars Win
Absolute dollar profit drives cash flow faster than margin percentage.
The prompt suggests the Premium device has a slightly lower percentage margin.
Still, every Premium sale contributes $417 toward fixed costs.
This maximizes the dollar amount covering overhead per transaction.
Are the 149% indirect COGS categories optimized for future volume?
Your 149% indirect COGS category needs immediate review, specifically the fixed production overheads, because these costs could quickly overwhelm your 686% gross margin if they don't scale well. For Tongue Retaining Device Sales, you've got to confirm that Quality Control Testing and Supervisory Indirect Labor costs remain variable or decrease as production volume rises.
Fixed Overhead Exposure
Indirect COGS sits at 149% of revenue, which is unsustainable.
Quality Control Testing is a fixed cost consuming 12% of revenue.
Supervisory Indirect Labor also consumes a fixed 12% of revenue.
These two line items alone account for 24% of revenue locked in place.
Scaling Margin Protection
Model how QC scales if volume doubles next quarter.
If supervisory staff doesn't increase, this percentage drops fast.
Focus on automating testing to convert QC from fixed to variable.
Where is the point of diminishing returns for the 80% Digital Marketing spend?
The point of diminishing returns for the 80% Digital Marketing spend is reached when the marginal cost of acquiring a new customer via digital ads exceeds the projected net present value of that customer, forcing a strategic reallocation toward fixed-cost investments like clinical sales personnel.
Digital Spend Saturation Point
Digital CAC (Customer Acquisition Cost) growth often becomes non-linear after initial efficient spend tiers.
When digital spend hits 80% of the total budget, variable costs quickly erode contribution margin.
Scaling further risks buying lower-quality leads who are less likely to adhere to treatment.
You must compare the cost of one more digital dollar against the cost of one more clinical sales hire.
Pivot to High-Value Channels
Shift focus to B2B channels like dental and sleep clinics for better volume.
Prioritizing the sales mix toward the high-dollar contribution Premium device ($495) over the Basic device is essential for maximizing transaction profitability.
Achieving 60%+ EBITDA margins requires rigorous optimization of both direct material costs and the substantial 149% indirect COGS structure.
Leveraging high-margin accessory attachment rates, like cleaning kits, creates predictable, high-frequency revenue streams that enhance long-term scaling efficiency.
Re-evaluating the 80% digital marketing spend is critical to ensure variable SG&A costs shrink proportionally as the business shifts focus toward higher-value clinical channels.
Strategy 1
: Prioritize High-Contribution Devices
Focus on Premium Profit
Direct your customer acquisition budget toward the $495 Premium device. This unit delivers almost twice the dollar profit of the $249 Basic model. Prioritizing higher-value sales immediately lifts your blended margin profile. That's just smart scaling.
Material Input Costs
Device production hinges on sourcing key parts like the $2,200 Titanium Screws and $1,200 Polymer. These costs feed into the $116 million annual direct COGS figure. You need supplier quotes now to model the impact of a 5-10% reduction.
Taming Sales Overhead
Variable SG&A runs high at 135%, driven by 80% digital marketing spend. If you push the Premium device through direct clinical channels instead of heavy digital ads, you can lower acquisition costs. That shift affects the 30% sales commission structure too. Defintely look at that trade-off.
Revenue Quality Check
Selling the $249 Basic unit might seem easy, but it pressures your 52% EBITDA margin goal. Every Premium sale at $495 pulls that blended margin up significantly. Don't chase low-quality volume just because it's easier to sell today.
Strategy 2
: Maximize Accessory Attachment Rate
Boost Aftermarket Profit
You need to push the $45 Cleaning Kit and $25 Liners hard right after the main sale. These add-ons create reliable, frequent income streams because they are consumables. The Liners, specifically, carry an incredible 760% gross margin, making them pure profit drivers. That's the fastest way to improve lifetime customer value.
Accessory Cost Structure
Focus on the gross profit potential of these consumables. The $25 Liners offer 760% margin, meaning for every dollar of cost, you generate $7.60 in profit before operating expenses. Estimate required inventory by projecting attachment rates onto the annual units produced of the main device. You need to know the unit cost of goods sold (COGS) for the $45 Kit to price it correctly.
Price Liners at $25.
Kit sells for $45.
Track attachment rate %.
Attachment Tactics
To lift attachment, integrate the offer directly into the checkout flow, perhaps bundling the Kit with the device for a slight discount. Avoid making the add-on feel like an afterthought; present it as essential maintenance. If onboarding takes 14+ days, churn risk rises if customers don't have the cleaning supplies ready. That's a defintely missed opportunity.
Bundle accessories at checkout.
Train sales on maintenance necessity.
Test mandatory initial kit inclusion.
Profit Lever
Consumables with margins this high directly impact your EBITDA margin, which is currently 52%. Every attachment sale acts like a small, immediate margin boost, offsetting pressure from fixed costs like the $28,200 monthly operating expenses. This revenue stream is far more stable than waiting for a 2029 price hike.
Strategy 3
: Reduce Material Input Costs
Target Material Input Costs Now
You must immediately target component sourcing to protect gross margin. Negotiating a 5-10% reduction on key inputs like the $2,200 screws and $1,200 polymer directly impacts your $116 million direct COGS base. This is low-hanging fruit for profitability improvement.
Understanding Material Spend
Direct Cost of Goods Sold (COGS) covers raw materials needed to build the oral appliances. You need the current unit cost breakdown for the $2,200 Adjustable Titanium Screws and the $1,200 Medical Grade Polymer. These two items are significant drivers within the total $116 million annual direct COGS.
Screws: $2,200 per unit.
Polymer: $1,200 per unit.
Total Annual Direct COGS: $116M.
Negotiating Component Pricing
Focus supplier negotiations on volume commitments for these specialized parts. If you achieve even a 7% cost reduction, that's nearly $8.1 million saved annually off the $116M COGS. Don't let supplier inertia stop you from pushing for better terms, especially given the high unit prices.
Target 5% to 10% reduction.
Calculate savings based on volume.
Avoid quality compromises for price cuts.
Actionable Sourcing Leverage
When talking to suppliers, frame the discussion around future volume projections rather than just current spend. If onboarding takes 14+ days, churn risk rises due to delayed cost savings implementation. You defintely need firm commitments by Q3 to realize full impact next fiscal year.
Strategy 4
: Scale Fixed Production Overhead
Overhead Growth Check
You must decouple fixed overhead growth from unit sales volume to fix the 149% indirect COGS. Keep costs like Factory Insurance (5%) and Regulatory Audit Fees (4%) from scaling too fast. This forces the gross margin percentage higher as you produce more units.
Insurance Cost Input
Factory Insurance (5% of indirect COGS) covers physical assets and liability at your production site. Estimate this based on the insured value of the facility and equipment, quoted annually. This is a fixed cost that shouldn't rise unless you expand the physical footprint significantly, regardless of unit count.
Facility asset valuation.
Annual premium quotes.
Fixed monthly expense.
Audit Fee Control
Regulatory Audit Fees (4%) are mandatory for medical devices but can be optimized. Bundle compliance checks when possible or negotiate fixed annual rates instead of per-incident billing. Avoid rushing audits, which forces premium service charges. It's defintely worth the effort.
Negotiate fixed annual contracts.
Bundle required compliance checks.
Avoid rush fees entirely.
Margin Lever
If you successfully grow unit volume while holding these fixed overhead percentages steady, the overhead cost per unit drops sharply. This directly improves the gross margin percentage, which is essential when fighting a bloated 149% indirect COGS figure.
Strategy 5
: Optimize Variable SG&A Spend
Cut Variable SG&A Burden
Your 135% variable SG&A, driven by 80% digital marketing and 30% commissions, is unsustainable for growth. You must test shifting volume to direct clinical channels immediately. This channel shift is the fastest way to lower customer acquisition costs (CAC) and improve margin quality, even if initial volume is slower.
Variable Spend Breakdown
These costs cover getting the device into the patient's hands. Digital marketing is the 80% spend on ads and content driving traffic. Sales commissions are the 30% paid out for closing deals, likely through referral partners or internal reps. Together, they eat up 135% of your baseline, meaning you lose money on every initial sale before fixed costs hit.
Model commission savings vs. clinical outreach cost.
Target CPAP-intolerant patients first.
Measure growth retention, not just initial volume.
Shift to Clinical Channels
Direct clinical channels bypass expensive digital funnels and high sales commissions. If a physician prescribes the device, the cost structure changes completely. You need to model the cost of a clinical partnership versus the 80% digital spend. It's about trading high-cost acquisition for higher-trust, lower-cost adoption.
Impact on Profitability
If clinical adoption replaces just half of your digital volume, you cut 40% from the 80% marketing spend and likely reduce the 30% commission structure substantially. This move immediately improves the overall 135% variable burden, freeing up cash needed to scale production or improve the 52% EBITDA margin target.
Strategy 6
: Control Non-Scaling Fixed Costs
Pin Down Fixed Spend
Your $28,200 monthly fixed operating expenses need immediate review to ensure they support scaling, not just historical inertia. Focus hard on the $5,000 Legal and Patent Maintenance and the $4,000 R&D Lab Maintenance line items. If these aren't driving immediate product updates or compliance for current sales channels, they are drag.
Scrutinize Specific Fixed Line Items
The $5,000 Legal and Patent Maintenance covers protecting your intellectual property, like the tongue-retaining mechanism design. The $4,000 R&D Lab Maintenance covers upkeep for equipment needed to test new polymer blends or device iterations. These costs total $9,000 monthly, or 32% of total fixed overhead, and must be defintely tied to growth.
Legal spend: $5,000 monthly
R&D Lab upkeep: $4,000 monthly
Total review amount: $9,000
Challenge Legacy Fixed Spend
Don't let old agreements dictate your burn rate. For legal costs, check if patent annuities can be deferred or if ongoing maintenance is required for patents not yet generating revenue. R&D lab costs should be tied to a clear product roadmap milestone; if the roadmap is paused, reduce the lab footprint or negotiate equipment leases down.
Tie R&D to active product launches
Audit all recurring patent fees
Seek lower maintenance contracts
Link Spend to Unit Economics
Every dollar in fixed overhead must be justified against the contribution margin of your devices. If the $495 Premium device is your focus, ensure the R&D spend is improving that specific unit or enabling a 760% margin accessory sale. Otherwise, cut it now.
Strategy 7
: Implement Strategic Price Increases
Price Hike Timing
You should test 3-5% price increases now because your premium positioning justifies moving faster than the planned 2029 adjustments. Waiting for the 2029 bump, like the Basic device moving from $249 to $255, leaves immediate margin expansion on the table for your 52% EBITDA margin.
Input Cost Context
Current pricing reflects high input costs, which supports a value-based price increase now. The Basic device sells for $249, but key components like the $1200 Medical Grade Polymer suggest high underlying cost pressure. You need to track the total direct COGS, currently $116 million annually, against unit volume to confirm price elasticity.
Basic Device Price: $249
Premium Device Price: $495
Annual Direct COGS: $116 million
Margin Leverage
Your 52% EBITDA margin is strong, but price hikes must be targeted to maintain patient acceptance in the medical space. Focus initial increases on the $495 Premium device, since it generates nearly double the dollar profit versus the $249 Basic model. This immediately improves your revenue quality.
Boost sales of the $495 Premium device.
Test 3-5% hikes on high-value customers first.
Ensure compliance documentation supports the higher perceived value.
Price Hike Risk
If you delay the 3-5% hike until 2029, you miss out on immediate cash flow to offset rising fixed costs like the $5,000 monthly Legal and Patent Maintenance. Your high-quality positioning is the shield; use it now to expand margins defintely.
Your current model shows a strong 52% EBITDA margin in Year 1, which is excellent for a medical device company By optimizing product mix and scaling efficiently, targeting 60-65% EBITDA is realistic as revenue hits $432 million
Focus on negotiating the largest direct material costs, such as the $7800 COGS for the Premium device Also, review the 149% indirect COGS; even a 1% reduction saves over $70,000 in Year 1 alone
About the author
Matthew Clarke
Founder Support Writer
Matthew Clarke is a founder support writer at Financial Models Lab, where he helps non-finance readers understand practical profit planning and how small businesses make a profit. He focuses on clear, research-based guidance before money is invested, including startup cost estimates and early planning basics. His work makes business planning easier, more practical, and less intimidating.
Choosing a selection results in a full page refresh.
